The stage and treatment of malignant neoplasm of maxillary sinus / Монголын Анагаах Ухаан

ABSTRACT

INTRODUCTION: Most patients with malignant neoplasm of maxillary sinus have no symptoms in the early stage and therefore, many of these patients are diagnosed in the advanced stage of the disease. The complexity of the anatomy and the proximity of the eyes, brain and cranial nerves render complete surgical resection difficult, which leads to local recurrence, a major cause of treatment failure. The incidence seems to vary in different parts of the world, with Asian countries reporting high numbers of cases. Malignant neoplasm of maxillary sinus is very difficult to treatment and traditionally has been associated with a poor prognosis. GOAL To study the stage and treatment of the malignant neoplasm of maxillary sinus. MATERIALS AND METHODS: 130 patients who had been diagnosed with malignant neoplasm of maxillary sinus at National cancer center of Mongolia between 1 January 2003 and December 2013 were reviewed. The following data were collected malignant neoplasm staging, types of treatment. Malignant neoplasm staging was done using the 7th edition of the American Joint Committee on Cancer (AJCC) classification, and retrospective restaging was done in previously diagnosed patients. RESULTS: There were 81 (62.4%) male and 49 (37.6%) female patients with a mean age of 53.18 years. Malignant neoplasms were classified retrospectively using the AJCC Staging System tumor classification was 5 (3.8%) were staged as II, 17 (13.1%) were staged as III, 108 (83%) were staged as IV, none stage as I. Malignant neoplasm of maxillary sinus to most infiltrated into nasal cavity (75 cases). In total, there 130 patients were submitted only to surgery 20.7%, to radiotherapy 22.3%, to chemotherapy 6.9%, to combination therapy 42.3%. CONCLUSIONS: 1.The higher the patient’s clinical stage was, the worse his prognosis was. 2. In this study the most commons treatment was combination of therapy. Combination of therapy may be the best treatment for patients with maxillary sinus malignant neoplasms.